Suzuki, Takeshi
Okamura, Akihiko http://orcid.org/0000-0002-3217-8888
Watanabe, Masayuki
Mine, Shinji
Imamura, Yu
Asari, Takao
Osumi, Hiroki
Nakayama, Izuma
Ichimura, Takashi
Ogura, Mariko
Ooki, Akira
Takahari, Daisuke
Yamaguchi, Kensei
Chin, Keisho
Article History
Received: 24 August 2019
First Online: 9 December 2019
Disclosure
: All authors declare no conflicts of interests for this article. Conflicts of interests outside this work are as follows; Kensei Yamaguchi played Consulting or Advisory Role for Bristol-Myers Squibb Japan and Daiichi Sankyo, and received Speakers’ Bureau from Chugai Pharma, Merck Serono, Bristol-Myers Squibb Japan, Takeda, Taiho Pharmaceutical, Lilly, Ono Pharmaceutical, Sanofi and Daiichi Sankyo. Kensei Yamaguchi’s institution (Department of Gastroenterological Medicine, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research) received research funding from MSD Oncology, Ono Pharmaceutical, Dainippon Sumitomo Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Lilly, Gilead Sciences, Yakult Honsha, Chugai Pharma, Boehringer Ingelheim and Eisai.